Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation

Cancer Journal

Volumn 8, Issue 4, 2002, Pages 322-327

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Lief, Jonathan H ^a,c   Galbreath, Robert W ^a,c   Adamovich, Edward ^d  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Biochemical outcome; Brachytherapy; High risk disease; Prostate cancer

Indexed keywords

HORMONE; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; PALLADIUM; RADIOACTIVE IODINE; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CALCULATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EVALUATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMPLANT; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MEDICAL SOCIETY; MONOTHERAPY; MULTIVARIATE ANALYSIS; ONCOLOGY; OUTCOME ASSESSMENT; PERINEUM; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RADIATION DOSE; RADIOISOTOPE THERAPY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ULTRASOUND; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RISK FACTORS; SURVIVAL RATE;

EID: 0036635920     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200207000-00008     Document Type: Article

References (29)

1. Merrick GS, Butler WM, Lief JH et al. Is brachytherapy comparable with radical prostatectomy and external beam radiation for clinically localized prostate cancer? Tech Urol 2001;7:12-19.
2. Blasko JC, Grimm PD, Sylvester JE et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
3. Ragde H, Korb LJ, Elgamal AA et al. Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135-141.
4. Critz FA, Williams WH, Levinson AK et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol 2000;164:738-743.
5. Singh A, Zelefsky MJ, Raben A et al. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Radiat Oncol Invest 2000;90:275-280.
6. Dattoli M, Wallner K, True L et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1999;45:853-856.
7. Potters L, Cha C, Oshinsky G et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999;5:301-306.
8. Blasko JC, Wallner K, Grimm PD et al. Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096-1099.
9. Zelefsky MJ, Hollister T, Raben A et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;47:1261-1266.
10. Merrick GS, Butler WM, Lief JH et al. Five-year biochemical outcome following permanent interstitial brachytherapy for T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:41-48.
11. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
12. Brachman DG, Thomas T, Hilbe J et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111-117.
13. American Society for Therapeutic Radiation and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
14. Fleming ID, Cooper JS, Henson DE et al. AJCC Cancer Staging Handbook, 5th edn. Philadelphia: Lippincott-Raven, 1998.
15. Merrick GS, Butler WM, Farthing WH et al. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachyther Int 1998;113-121.
16. Nath R, Anderson LL, Luxton G et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 1995;22:209-234.
17. Merrick GS, Butler WM, Dorsey AT et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 2000;46:215-220.
18. Merrick GS, Butler WM, Wallner KE et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Radiat Oncol Invest, in press.
19. Butler WM, Merrick GS, Lief JH et al. Comparison of seed loading approaches in prostate brachytherapy. Med Phys 2000;27:381-392.
20. Merrick GS, Butler WM. Modified uniform seed loading for prostate brachytherapy: rationale, design, and evaluation. Tech Urol 2000;6:78-84.
21. Merrick GS, Butler WM, Dorsey AT et al. Potential role of various dosimetric quality indicators in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:717-724.
22. Merrick GS, Butler WM, Dorsey AT et al. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 2001;7:233-240.
23. Valicenti R, Lu J, Pilepich M et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated in the Radiation Therapy Oncology Group trials. J Clin Oncol 2000;18:2740-2746.
24. Do TM, Parker RG, Smith RB et al. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001;57:1121-1127.
25. Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-623.
26. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Oncology Group Protocol 85-31. J Clin Oncol 1997;15:1013-1021.
27. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
28. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
29. Potters L, Torre T, Ashley R et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000;18:1187-1192.